Impact of COVID-19 on Business Operations, Clinical Trials and Orders
First written in FY2020. 4 of 11 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024RestatedAnnual report
「Since COVID-19 was reclassified as a Category 5 infectious disease under the Infectious Diseases Control Law, domestic demand has been on a recovery trend as restrictions on activities have been eased.」
The Company continues to explain that the easing of restrictions on activities after COVID-19's reclassification as a Category 5 infectious disease has reduced the previous impact of COVID-19 and that domestic demand is recovering. - FY2024-Q3MitigatedAnnual report
「Since COVID-19 was reclassified as a Category 5 infectious disease under the Infectious Diseases Control Law, domestic demand has been on a recovery trend as restrictions on activities have been eased.」
The filing states that domestic demand is recovering as a result of COVID-19's reclassification as a Category 5 infectious disease and the easing of restrictions on activities. The previous business impact from restrictions on visits and stagnant demand has partially eased. - FY2023-Q3WorsenedAnnual report
「Compared with previous waves of COVID-19 infections, the seventh and eighth waves had lower rates of severe illness but were highly infectious, and infections among doctors and medical staff strained human resources. As a result, not only were more scheduled surgeries cancelled than before, but there was also a pronounced impact from medical institutions avoiding or postponing treatments using the Company's products, which require substantial staffing.」
During the seventh and eighth waves, infections among doctors and medical staff strained human resources, leading not only to cancellations of scheduled surgeries but also to a more pronounced increase than before in the avoidance and postponement of treatments using the Company's products. - FY2023-Q2WorsenedAnnual report
「Although the risk of severe illness was low, the highly infectious seventh wave had a significant impact on the use of the Company's products, which are primarily used in scheduled surgeries, as many surgeries were cancelled after doctors or patients tested positive immediately before surgery.」
Even after restrictions on activities were eased, the seventh wave led to frequent surgery cancellations following positive tests among doctors and patients, resulting in a significant actual impact on the use of the Company's products. - FY2023-Q1MitigatedAnnual report
「As restrictions on visits to medical institutions and on holding academic conferences due to COVID-19 were eased, the Company resumed sales activities while carefully assessing the situation.」
As restrictions on visits and on holding academic conferences due to COVID-19 were eased, conditions allowed sales activities to resume, partially reducing the previous impact on sales activities and orders. - FY2022-Q2MitigatedAnnual report
「Some clinical trials and other activities resumed at companies and academic institutions where development had been delayed by COVID-19, leading to progress in contract work on multiple projects. However, sales overall declined from the same period of the previous year because some projects were delayed or had their schedules changed.」
While development delays caused by COVID-19 remained, some clinical trials and other activities resumed at companies and academic institutions, and contract work on multiple projects progressed, partially reducing the impact. However, delays and schedule changes continued in some projects. - FY2022-Q1MitigatedAnnual report
「As some clinical trials and other activities resumed at companies and academic institutions where development had been delayed by the effects of COVID-19, contract work progressed on multiple projects.」
Although development stagnation and clinical trial delays in COVID-19-related contract projects remained, some clinical trials and other activities resumed and multiple projects progressed, partially reducing the impact. - FY2021-Q3Continued decline in contract revenue and resumption of developmentAnnual report
「Sales declined substantially because clinical trials and technology transfers from overseas were delayed at contracting parties, including companies and academic institutions, that were heavily affected by the spread of COVID-19 in the first half. From the third quarter onward, companies and academic institutions showed clear signs of resuming development, including clinical trials, and contracts were signed in multiple projects for the next development stage, making revenue generation in the fourth quarter foreseeable.」
While stalled development, delayed clinical trials and overseas technology transfers, and declining sales at contracting parties due to COVID-19 continued, customers resumed development and contracts were signed for multiple projects. - FY2021-Q2MaterialisedAnnual report
「Revenue from the regenerative medicine contract business for the cumulative second quarter period under review was ¥212,847 thousand, down 29.8% year on year. Development stalled at medical institutions and companies heavily affected by the spread of COVID-19, and delays in clinical trials and overseas technology transfers continued, resulting in a substantial decline in revenue from the same period of the previous year.」
The impact of COVID-19 continued to affect the contract business, with stalled development, delays in clinical trials and overseas technology transfers, and an actual 29.8% year-on-year decline in sales. - FY2021-Q1MaterialisedAnnual report
「Revenue from the regenerative medicine contract business for the cumulative first quarter was ¥73.724 million, down 40.6% year on year. At medical institutions and companies commissioning work that were significantly affected by COVID-19, development not only stalled, but clinical trial starts and technology transfers overseas were also delayed, resulting in a substantial decline in revenue from the same period of the previous year.」
The impact of COVID-19 also extended to the contract business, becoming evident in stalled development, delays in starting clinical trials and transferring technology overseas, and a 40.6% year-on-year decline in sales. - FY2020MaterialisedAnnual report
「In the research and development support business, orders for the Company's products have declined sharply because researchers at customers' companies and research institutions have begun working from home, resulting in the postponement of experiments and evaluations.」
The filing states that COVID-19 had concrete impacts across the business, including the voluntary suspension of sales visits to medical institutions, a decline in product use and clinical trial participation, development delays at contracting parties, and a sharp decline in orders for research and development support products. It also states that the impact on the fiscal year under review was limited and minor and that there was no impact on the Company's ability to continue as a going concern.